Bitte aktivieren Sie Javascript um alle Funktionen nutzen zu können und ihre Nutzererfahrung zu verbessern.
GfV 2023
Programm
Poster
Personen
Suche
EN
Alle Personen
Prof. Dr. Asisa Volz
Hannover / DE
University of Veterinary Medicine Hanover
Sortiert nach Typ
Datum
Vorsitz
29.03.2023
13:30
–
15:00
Workshop
Adaptive immunity 2
Lecture hall 4/5
Weitere Beteiligungen
28.03.2023
Poster
P 293
Stabilized recombinant SARS-CoV-2 spike antigen enhances vaccine immunogenicity and protective capacity
Adaptive immunity, Vaccines
28.03.2023
Poster
P 312
In vitro characterization of three MVA based candidate vaccines expressing SARS-CoV-2 envelope, ORF3a and membrane proteins
Vaccines
28.03.2023
Poster
P 313
In vitro characterization of two MVA candidate vaccines expressing the fusion and matrix proteins of Nipah virus
Emerging viruses and zoonosis, Vaccines
28.03.2023
Poster
P 316
Impact of heterologous MVA-booster vaccination on SARS-CoV-2 specific immune responses in a Golden Syrian Hamster model for Coronavirus disease 2019 (COVID-19)
Adaptive immunity, Vaccines
28.03.2023
Poster
P 110
Induction of fetal protection against Zika virus induced by a MVA-prME candidate vaccine
Emerging viruses and zoonosis, Vaccines
28.03.2023
Poster
P 012
CD8+ T cell mediated protection against Zika virus induced by recombinant modified Vaccinia virus Ankara expressing ZIKV non-structural protein NS2B
Adaptive immunity
28.03.2023
Poster
P 317
Generation and in vitro characterization of two recombinant MVA candidate vaccines expressing Marburg virus glycoprotein and nucleoprotein
Emerging viruses and zoonosis, Vaccines
28.03.2023
Poster
P 128
Generation and in vitro characterization of MVA-based vaccines targeting selected influenza A virus hemagglutinin proteins
Emerging viruses and zoonosis, Vaccines
29.03.2023
11:30
–
11:45
12 Min.
3 Min.
Abstract Talk
O 047
Single MVA-MERS-S vaccination activates spike antigen specific T cells in dromedary camels under field conditions
Adaptive immunity
31.03.2023
10:45
–
11:00
12 Min.
3 Min.
Abstract Talk
O 115
MVA-HBVac – a novel vector for treatment of chronic hepatitis B via therapeutic vaccination
Adaptive immunity, Vaccines
© Conventus Congressmanagement & Marketing GmbH
Impressum
Datenschutz